|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
"Well-diversified mix of health care, pharmaceuticals, and medical devices"![]() |
97%
agree
35 votes
|
Cash, yield and low P/E |
100% agree |
Cash, yield and low P/E![]() |
100%
agree
3 votes
|
Price Target: $68.00, 4 reasons |
66% agree |
Price Target: $68.00, 4 reasons![]() |
66%
agree
3 votes
|
Generics eat into profits |
50% agree |
Generics eat into profits![]() |
50%
agree
8 votes
|
FDA warnings are bad for business |
0% agree |
FDA warnings are bad for business![]() |
0%
agree
2 votes
|
Drug development is costly and its success is inherently risky![]() |
41%
agree
12 votes
|
|
| Table of Contents |
| Intro and Overview |
| Introduction |
| Business Overview |
| Trends and Forces |
| Key Trends and Forces |
| Competition |
The consumer health market is expanding as consumers are taking greater responsibility and interest in their own health. Johnson & Johnson owns highly successful brands such as Tylenol, Band-Aid, and Neutrogena. The acquisition of Pfizer's Consumer Healthcare division in 2006 and addition of brands such as Listerine, Lubriderm, Visine, and Neosporin further solidified Johnson & Johnson dominance in consumer health care.
The company's pharmaceutical segment faces many of the challenges that face all pharmaceutical companies, including issues surrounding patent expiration and FDA approval. In addition, there are constant threats of litigation and a growing pressure in the US and abroad to lower the price of medication.
Johnson & Johnson Corporation was founded in 1886 by Robert Wood Johnson, an American entrepreneur and Industrialist. Inspired by the developing scientific understanding of proper of sanitation, Johnson aimed to make antiseptic surgical procedures easier. Through numerous targeted acquisitions and research over the next century, the company steadily diversified its business to encompass pharmaceutical, medical devices, and consumer packaged goods.
Johnson & Johnson has interests in a broad spectrum of the health care market, and takes a decentralized approach to managing its 250 operating companies and franchises. In the company's continuing effort to diversify its business and increase profits, Johnson & Johnson is constantly acquiring new companies, including 8 in the last year alone. In 2007, worldwide sales totaled $61.1 billion, making Johnson & Johnson the second largest manufacturer of health care products, behind Pfizer.
Johnson & Johnson's 2009 first quarter net income fell by 2.5% to $3.5 billion compared to $3.6 billion a year ago. Quarterly sales fell by 7.2 percent to $15 billion, well below the forecast of $15.43 billion, but this is largely attributable to a stronger dollar (sales fell 1% when controlling for currency fluctuations). Net income was not as adversely affected due to Johnson & Johnson's efforts to cut spending on administration, sales, and R&D.[1]
The company consists of three major divisions: consumer healthcare, medical devices, and pharmaceuticals.
Consumer products are non-prescription health care products marketed directly to the general public. Johnson & Johnson has diverse franchises in over-the-counter pharmaceuticals and nutritionals, skin care, baby & kids care, and women's health products, totaling $16.0 billion in sales in 2008.[3] Although the Consumer Health Care division is the smallest of the company's three segments, it includes some of the company's most recognizable brands such as Tylenol, Neutrogena, and Band-Aid.
In 2006, Johnson & Johnson bought Pfizer's Consumer Healthcare for $16.6 billion. This acquisition represents a significant expansion in Johnson & Johnson's Consumer Health Care division, adding brands such as Listerine, Sudafed, and Neosporin.
The Pharmaceutical division is the largest of the three business segments, bringing in $24.6 billion in revenue for 2008.[5] Pharmaceutical products are usually prescription medications distributed to retailers, wholesalers, and health care professionals. Johnson & Johnson's pharmaceutical program is ranked third in sales in the United States and fourth in the world. It uses the same business model and faces similar challenges as other major pharmaceutical companies.
Of Johnson & Johnson's pharmaceutical portfolio, the four most successful drugs each brought in over $2 billion in 2008 annual revenue, and are:
Johnson & Johnson is the world's largest developer and manufacturer of medical treatment and diagnostic devices, with annual sales of $23.1 billion.[6] This segment includes a wide variety of equipment and supplies used mostly in the professional fields, by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. Major franchises in this division include:
On December 1st, 2008, Johnson & Johnson announced plans to purchase breast-implant maker Mentor (MNT) for $1.07 billion. Mentor's revenues were lower in 2008, attributable largely to decreased spending on cosmetics due to the 2008 global recession. The acquisition will allow J&J to enter the market of medical cosmetics, both through Mentor's breast implant business and through its wrinkle remover PurTox, a rival to Allergan (AGN)'s Botox. [7](Read more about Johnson & Johnson's key trends and forces...)
|
Worried about pump and dump?
We review changes
for stock spam |
Want to make Wikinvest better?
We need your help,
contribute today |
Do you write software?
We are recruiting
the best engineers |
Like Wikinvest?
Spread the word —
Tell your friends! |